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Before going into a discussion of the diagnosis
and treatment of carcinoma of the thyroid, I would
like to make a few observations on the means of
detection.
Thyroid scanning, in my opinion, is useful only
in the study of nodules. We see many patients who
have had scans for diffuse thyroid enlargement, and I
feel that in this instance, scans are useless. The basic
reason for the scan is to discover which pieces of
thyroid tissue have to be removed because of possible
malignancy. I would like to emphasize, that the
physician has to do the scan himself. He has to
localize the nodule, properly mark it on the scan, and
remain during the scan, as the patient may move his
neck, thus moving the position of the nodule in
reference to the marks. We have seen scans in the
early days of isotope scanning where the technician,
who was not taught to palpate the thyroid, marked
the scan. This system is inadequate, as errors can occur.
Using the T-3 suppression test, the criteria for
suppression is a fall in uptake below 20% in 24 hours
after a week on T-3, 150µ daily. However, the normal
uptake is often below 20%, and hyperthyroid patients
may also have less than 20% uptake, so the test is losing some of its specificity. I think the criteria for the
suppression test should be changed, or the interpretation of it, to indicate that there is "no significant" fall
in uptake after T-3 for a week. It is very difficult to establish such criteria, because I do not know what normal figures to give. We recently saw a patient with a
• The following is an edited transcription of a lecture presented by
Dr. Kirkland at the Postgraduate Course in Nuclear Medicine,
February 27, 1975, in Williamsburg, Virginia.
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nodule who had 8% uptake in 24 hours prior to T-3.
We went ahead with T-3 suppression, and he had 7%
after T-3. We did not know what to do or how to interpret this. We treated the patient with radioactive
iodine, thinking that the nodule was not suppressible,
and the other lobe did reappear on later scanning.
This patient had an autonomous nodule with an 8.0%
uptake.
In my opinion, 3- and 5-hour uptakes are absolutely essential. I would not want an uptake run
only at 24-hour intervals, because we do see patients
who have taken iodides or, unknown to us, antithyroid drugs and who have normal 24-hour uptakes but who have blocked thyroid function and are
not making thyroid hormone at the moment.
Therefore, it is necessary to run 3- and 5-hour uptakes to identify this blocked type of function and, if
diagnosis is not clear at that time, at a later 24-hour
· point.
In the hot nodule with low radioiodine uptake
where the T-3 suppression test may not be of great
value, one can give TSH and do a scan afterward to
see if the other lobe reappears. If it does reappear, indications are that the nodule is an autonomous one
which was suppressing TSH.
I now want to discuss the diagnosis and treatment of carcinoma of the thyroid. Carcinoma of the
thyroid gland is both rare and common. It is a frequent diagnosis on pathological sections, but clinically it is a rare disease. Very few patients die from
carcinoma of the thyroid. Each of us has seen so few
thyroid carcinomas of clinical significance that it is
difficult to gather a series sufficiently large to determine what treatment techniques are best. As some
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evidence of the incidence, Dr. Fratkin showed that in
one hundred cases of thyroid nodules 70% were cold.
Of the 70% that were cold, he said 15% were carcinomatolis. That is a high incidence of carcinoma of
the thyroid. Recently, a student and I went around on
the wards at the Medical College of Virginia and felt
every patient's thyroid reg; rdless of what the patient
had been admitted for . Thirty-three percent of the
women incidentally had palpable nodular thyroid
disease. If we take these female patients with
nodules-70% of them cold and 15% of them with
carcinoma-3.48% of women in the Medical College
of Virginia should have carcinoma of the thyroid.
Obviously these figures are not true clinically. Even
the pathologist has problems in diagnosing thyroid
malignancy. Thyroid-stimulating hormone stimulation of the thyroid makes it so hypertrophic that
sometimes the thyroid looks malignant although it
doesn't behave that way.
In patients with carcinoma of the thyroid, the
natural course of the disease is variable, so that a
long-term follow-up is necessary to determine what
happens to them. One cell type, such as papillary carcinoma of the thyroid, might change to follicular, or
the metastases may show at the same time different
pathological types. Any treatment I propose,
therefore, would have to be very arbitrary.
I would like to mention something about the
etiology of the carcinoma of the thyroid. Two
Australians, Purves and Geishbach, in 1948, gave rats
thiourea for two of their three-year life spans and
found that 100% of the rats developed carcinoma of
the thyroid. (This fact does not stop us from giving
propylthiouracil to patients, and some clinics advocate this as the best treatment for
hyperthyroidism). They stated in their article, "We
think that the administration of thyroid extract to
these rats would have prevented this." They gave
thiourea to rats after. hypophysectomies and none of
these animals developed carcinoma of the thyroid.
This suggests to me that the etiology for the carcinoma, or an etiological factor, was the TSH level
which rose in the thiourea-treated rats and stimulated
a blocked gland. That was the first finding that led me
to think that carcinoma might be produced by longterm TSH stimulation of a blocked or damaged
thyroid gland. There is also an increased incidence of
carcinoma of the thyroid in patients who have congenital enzyme blocks. One type of congenital enzyme block is followed by nearly 100% incidence of
carcinoma of the thyroid-another fact that makes

me think that TSH stimulation might lead to carcinoma. There is a higher incidence of carcinoma of
the thyroid in thyroiditis where the gland may be injured. The TSH may rise and the same circumstances
occur. Irradiation of the neck in childhood is another
etiologic factor. There are also cases of thyroid carcinoma which are TSH dependent. These tumors
tend to grow more rapidly if the TSH levels are high.
We should, therefore, keep the TSH low in patients
who have carcinoma of the thyroid. This concept has
been an important influence in my treatment of
thyroid patients. Once hyperthyroidism is eliminated,
I think anyone with thyroid disease should be on
long-term suppressive thyroid hormones.
These factors led me to review the histories of
patients with carcinoma of the thyroid at the Medical
College of Virginia in order to see if I could find a
thyroid-damaging factor. Fifty percent of the patients
had had some thyroid destructive disease, such as
thyroiditis or colloid goiter, or treatment for thyroid
suppression, such as surgery. None of them had had
radioiodine therapy, but I think the incidence of carcinoma of the thyroid might increase after radioiodine if we live long enough to observe this course.
How do we diagnose the carcinoma of the
thyroid? Most cases are not diagnosed by symptoms,
although there are some symptoms, such as
hoarseness or a tracheal narrowing shown on AP and
lateral x-rays. Hoarseness suggests that the recurrent
laryngeal nerves might be invaded, and this might indicate the possibility of carcinoma, especially if it is
accompanied by a mass in the thyroid area.
Dysphagia is suspicious. X-ray studies of the esophagus showing real obstruction are helpful and do
suggest that there is true disease present and not just
an anxiety globus hystericus. We recently noted a
bruit over the thyroid gland in the absence of
hyperthyroidism. This indicated that there was high
vascularity and suggested the possibility of
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Fig. I-Pathology in "hot" nodules at MCV.
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Pathology found in cold nodules ( 184)
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Fig. 2-Pathology is 184 cold nodules at MCV.

malignancy. A distant metastasis might be a hint of
carcinoma of the thyroid. If there are nodules, we
want to do scans. If the scan shows a cold nodule,
carcinoma is a prime possibility. Figure I shows the
pathology we have seen in our "hot" nodules.
Nodular colloid goiter was found in 70% of cases,
hyperplastic goiter (we are not sure what the
pathologist meant by this as these were supposedly
nontoxic patients) in 15%, adenoma in 15%, but no
carcinoma. Figure 2 shows the pathology in 184 cold
nodules which were removed . Thirteen percent were
carcinomas of the thyroid.
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Fig. 3-AP scan of patient with suspect nodule.
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I want to emphasize the importance of lateral
scans. Figure 3 is an AP scan of a patient who had
had a nodule. One might think that this was a functional nodule and not malignant. But on the lateral or
oblique scan (Fig. 4), a cold nodule is seen in front of
the radioactivity. Figure 5 shows a nodule that might
be interpreted as a hot nodule. There is suspicion that
it might not be a hot nodule, however, for the center
of the gland is thicker, and one would think it would
have a higher radioactivity. On the lateral scan, it is
confirmed as a cold nodule.
The treatment of carcinoma of the thyroid varies
with the cell type, and Figure 6 snows the main types
of the disease. The first approach to treatment of carcinoma of the thyroid is surgery. The extent of the
surgery depends on the type of lesion. A biopsy with
a frozen section will indicate what type of malignancy
one is dealing with. The nodule should be removed
along with any suspect tissue, and if it is carcinoma
on a frozen section, a total thyroidectomy is indicated. The only exception would be that I would
ask the surgeon not to take the parathyroid glands.
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Fig. 5-Left. AP scan of possible cold nodule; Right. Confirmed on lateral scan.

As this might be difficult, he would perform a nearly
total thyroidectomy. Myxedema as a result of surgery
is of no concern because the patient will be placed on
thyroid extract. All patients with carcinoma of the
thyroid should be on thyroid extract for the rest of
their lives in the hope that hormonal suppression of
the tumor will be achieved, just as one might treat
carcinoma of the breast with appropriate hormonal
treatment. Radical neck dissection is not often my
choice. The surgeon usually decides this. If he feels
that the nodes are within the range of surgical resection, he should try to get them out, but in my opinion, severely disfiguring, radical neck dissection is of
no great value. The prognosis for carcinoma of the
thyroid is so good that, other than for anaplastic
types, I would not urge extensive neck dissection. In a
medullary carcinoma, there is one follow-up technique
and that is to check on calcitonin levels, because
this offers a marker for continuing disease. If the
calcitonin levels were high before removal and

afterwards fell to normal, it would be very reassuring
that the malignancy had been completely removed. If
calcitonin levels rose in the future, they would indicate that the carcinoma had recurred and that
further treatment should be considered.
There is a difference of opinion regarding the
surgical follow-up schedule. Some authors would
wait a month and do a radioactive iodine uptake

Classification of Thyroid Neoplasms
A. Adenoma
B. Carcinoma
I. Adenoma malignum
2. Papillary
3. Follicular
4. Medullary
5. Anaplastic

Fig. 6-Main types of thyroid disease.
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study to see if there is any residual thyroid tissue in
the neck. They would ablate it with radioactive iodine
and put the patient on thyroid hormone while waiting
to see whether the patient develops further disease.
This seems to me unnecessary as the patient may have
already been cured. I would put the patient on
thyroid hormone after the initial thyroidectomy and
wait. If disease appears, I would stop the thyroid
replacement and do a 131 1 scan. If there is uptake of
131 I in the residual thyroid area, a thyroid ablative
dose of 131 1 should be given. In one to two months, a
tracer dose should be given to see whether there is
any retention of the isotope after 48 hours. At the
Medical College of Virginia, we determine 24- and
48-hour urinary excretions of 1311 at that stage, and if
there is any significant retention (if the patient excretes less than 90% of the radioiodine in the urine in
48 hours), we scan the whole body searching for areas
of retention and treat with large doses of radioiodine.
If there were significant retention, we would try to
stimulate maximal uptake of radioactive iodine prior
to treatment by giving TSH intravenously or intramuscularly for three days and repeat the 1311 uptake.
Should there be increasing retention, I would keep up
the TSH for three more days until the maximal uptake
was reached, because this may be the only opportunity
to get an excellent uptake in the tumor. Therefore, I
would continue TSH until I obtained maximum
retention of the tracer dose, then give a large dose of
radioactive iodine (150 millicuries of radioiodine),
hoping to obtain the maximum uptake in the tumor.
After radioiodine had had a chance to accumulate
in the gland, I would put the patient on triiodothyronine ( one of the few clinical uses for this

hormone in treatment) in order to suppress TSH in
the interim, while waiting for the effect of the dose.
The patient should be kept on that dose for about six
weeks. The dose should then be discontinued and the
patient retested with radioactive iodine in eight
weeks. As long as there is uptake of radioactive
iodine or retention of the isotope with less than 90%
excretion in 24 hours, I would continue to treat the
patient with radioactive iodine at approximately twomonth intervals until I had no further retention of the
radioactive material. Of course, this has to be
monitored by blood counts, primarily platelet counts.
We have not seen significant platelet reduction until
we have given 300 to 400 millicuries of radioiodine.
Once I had achieved as much radioactive iodine treatment as possible, that is, there was no longer any
retention of the isotope 48 hours after a tracer dose, I
would put the patient on totally suppressive and
replacement doses of levothyroxine or triiodothyronine. The triiodothyronine is used because it
can be stopped more quickly, and its effect disappears
more quickly. An additional method of treatment
to consider, when radioactive treatment was no
longer effective, would be x-ray therapy to any areas
that were causing symptoms.
The major point I would like to make is that we
should try to prevent thyroid carcinoma by administration of thyroid hormones to all patients with
potentially high TSH and damaged-thyroid disease,
using suppressive doses of levothyroxine. In my opinion, all patients who have thyroid disease should be
treated with thyroid hormone indefinitely, once
hyperthyroidism has been eliminated.

